December 3, 2020

Durablity of response to COVID-19 mRNA-1273 vaccination

By: Judy Mathias

Editor's Note

This study led by the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, finds that vaccinations with mRNA-1273 (Moderna) have the potential to provide durable humoral immunity.

This report describes immunogenicity data for mRNA-1273 at 119 days after the first vaccination and 90 days after the second vaccination in 34 adult participants in Moderna’s trial.

Sponsored Message

At a dose of 100-µg, the vaccine produced high levels of binding and neutralizing antibodies that declined slightly as expected but remained elevated in all participants 3 months after the booster vaccination. Neutralizing antibodies continued to be found in all participants at day 119.

During the trial, no serious adverse events were noted, no prespecified trial-halting rules were met, and no new adverse events related to the vaccine occurred after day 57.

Though the memory cellular response to mRNA-1273 is not yet defined, the vaccine elicited primary CD4 type 1 helper T-cell responses 43 days after the first vaccination, the researchers say, and studies of vaccine-induced B cells are ongoing.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat